White Rose Research Online

eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk
Universities of Leeds, Sheffield and York

Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:
https://eprints.whiterose.ac.uk/id/eprint/87845/

Version: Accepted Version

Article:

Oftedal, B.E., Hellesen, A., Erichsen, M.M. et al. (2015) Dominant Mutations in the Autoimmune Regulator AIRE Are Associated with Common Organ-Specific Autoimmune Diseases. Immunity , 42 (6). 1185 - 1196. ISSN: 1074-7613

https://doi.org/10.1016/j.immuni.2015.04.021

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

UNIVERSITY OF LEEDS
University of Sheffield
UNIVERSITY of York

Dominant *Autoimmune Regulator* mutations associated with common organ-specific autoimmune diseases

Bergithe E. Oftedal[1], Alexander Hellesen[1,2], Martina Moter Erichsen[2], Eirik Bratland[1], Ayelet Vardi[3], Jaakko Perheentupa[4], E. Helen Kemp[5], Torunn Fiskerstrand[1,6], Marte K. Viken[7], Anthony P. Weetman[5], Sarel J. Fleishman[8], Siddharth Banka[9, 10], William G. Newman[9, 10], W.A.C Sewell[11], Leila S. Sozaeva [12], Tetyana Zayats[13], Kristoffer Haugarvoll[14], Elizaveta M. Orlova[12], Jan Haavik[13], PhD Stefan Johansson[1,6], Per M. Knappskog[1,6], Kristian Løvås[1,2], Anette S. B. Wolff[1], Jakub Abramson[3ε], Eystein S. Husebye[1,2ε*]

Affiliations:

[1] Department of Clinical Science, University of Bergen, 5021 Bergen, Norway.

[2] Department of Medicine, Haukeland University Hospital, 5021 Bergen, Norway.

[3] Department of Immunology, The Weizmann Institute of Science, 76100 Rehovot, Israel.

[4] Hospital for Children and Adolescents, University of Helsinki, Finland.

[5] Department of Human Metabolism, The Medical School, University of Sheffield, Sheffield S10 2RX, UK

[6] Center for Medical Genetics and Molecular Medicine, Haukeland University hospital, 5021 Bergen, Norway.

[7] Department of Immunology, Oslo University hospital and University of Oslo, Norway.

[8] Department of Biological Chemistry, The Weizmann Institute of Science, 76100 Rehovot, Israel.

[9] Manchester Centre for Genomic Medicine, University of Manchester, Manchester, M13 9WL, UK.

[10] Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester Academic Health Sciences Centre, Manchester, M13 9WL, UK.

[11] Path Links Immunology, Scunthorpe General Hospital, Scunthorpe, DN15 7BH, UK.

[12] Endocrinological Research Center, Institute of Pediatric Endocrinology, Moscow, Russian Federation

[13] K.G. Jebsen Centre for Neuropsychiatric Disorders, Department of Biomedicine, University of Bergen, 5021 Bergen, Norway

27 [14] Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway

28 [ε] ESH and JA have contributed equally to the study

29 *Corresponding author: Phone: 55973077; Fax 55972950; Department of Clinical Science,

30 University of Bergen, 5021 Bergen, Norway. e-mail: eystein.husebye@k2.uib.no

Summary

The autoimmune regulator (*AIRE*) gene is crucial for establishing central immunological tolerance and the prevention of autoimmunity. Mutations in *AIRE* cause a rare autosomal recessive disease, autoimmune polyendocrine syndrome type 1 (APS-1), distinguished by multi-organ autoimmunity. We here report multiple cases and families with mono-allelic mutations in the first plant homeodomain (PHD1) zinc finger of AIRE, which follow dominant inheritance, typically characterized by later onset, milder phenotypes, and reduced penetrance compared to classical APS-1. These missense PHD1-mutations suppress gene expression driven by wild type AIRE in a dominant negative manner, unlike CARD or truncated AIRE mutants, which lack such dominant capacity. Strikingly, exome array analysis revealed that the PHD1 dominant mutants are found with relatively high frequency (> 0.0008) in populations. Our results provide novel insight into the molecular action of AIRE and demonstrate that disease-causing mutations in the *AIRE* locus are more common and variable than previously appreciated.

46 ## INTRODUCTION

47 The autoimmune regulator (*AIRE*) is a key player in shaping central immunological tolerance
48 to self. AIRE is mainly expressed in medullary thymic epithelial cells (mTECs), but to some
49 extent also in rare hematopoietic populations of lymph nodes (Gardner et al., 2008). In
50 mTECs, AIRE induces expression of thousands of tissue-restricted proteins, which are
51 presented on major histocompatibility complex class I (MHC-I) and MHC-II molecules to
52 developing T cells, percolating through the thymic medulla. This “projection of self” by
53 mTECs is essential for the elimination of auto-reactive T cells, either via clonal deletion
54 (Taniguchi and Anderson, 2011) or via their conversion into Foxp3+ regulatory T cells (Cowan
55 et al., 2013); a critical step for the induction of functional immunological tolerance to self
56 and prevention of autoimmunity (Taniguchi and Anderson, 2011).

57 In humans, mutations in the *AIRE* gene cause autoimmune polyendocrine syndrome
58 type 1 (APS-1), also called autoimmune polyendocrinopathy–candidiasis–ectodermal
59 dystrophy (APECED), a rare autosomal recessive disease characterized by autoimmune
60 attack against peripheral (mainly endocrine) tissues, as well as by generation of various
61 autoantibodies, including interferon-specific autoantibodies (Meager et al., 2006). The
62 majority of APS-1 patients develop at least two (diagnostic dyad) of the three main
63 components, including adrenocortical insufficiency, hypoparathyroidism and chronic
64 mucocutaneous candidiasis (Ahonen et al., 1990; Husebye and Anderson, 2010). In addition,
65 premature ovarian insufficiency, pernicious anemia, vitiligo, alopecia, enamel hypoplasia,
66 and keratitis are common components. The disease typically manifests in childhood, but
67 milder forms with late debut are seen, which are not always recognized as APS-1 at first.

68 About 100 APS-1-causing mutations have been found throughout the *AIRE* gene
69 (http://www.hgmd.cf.ac.uk) (Ferguson et al., 2008). All are assumed to be inherited in an
70 autosomal recessive manner, except for one mutation in the SAND-domain, p.G228W, which
71 follows a dominant inheritance pattern (Cetani et al., 2001). Since AIRE is known to operate
72 as a homo-oligomer (Kumar et al., 2001; Pitkanen et al., 2000), it is rather surprising that
73 only one mono-allelic mutation in the *AIRE* locus has been linked to APS-1 and/or other
74 forms of organ-specific autoimmune disorders so far.
75 Based on analysis of human patients followed by biochemical and population
76 analyses, we here report a group of novel mono-allelic *AIRE* mutations. These mutations
77 cluster within the first plant homeodomain (PHD1) zinc finger domain, associate with organ-
78 specific autoimmune diseases with varying penetrance and severity, sometimes, but often
79 not matching the diagnostic criteria of APS-1. Furthermore, we delineate the molecular
80 mode of action by which these unique mutations interfere with the function of wild type
81 (WT) AIRE protein. Our results provide novel insights into the molecular action of the AIRE
82 protein and indicate that disease-causing mutations in the *AIRE* locus are much more
83 common than previously thought and can cause more variable autoimmune phenotypes.
84

85 **RESULTS**

86 **Novel p.C311Y AIRE mutant exerts a dominant negative effect**

87 The study was initiated by the discovery of a heterozygous c.932G>A (p.C311Y) mutation in
88 *AIRE* in a North-African patient (I:2, **Figure 1A, Table 1 and Table S1**) diagnosed with adult-
89 onset of chronic mucocutaneous candidiasis, adrenal insufficiency, enamel dysplasia,
90 pernicious anemia, partial diabetes insipidus, and interferon omega autoantibodies (**Figure**

91 **1A**). Importantly, no other mutations or copy number variations were detected. His family
92 history revealed a daughter (II:1, with partner 1) who had hypoparathyroidism, enamel
93 dysplasia, primary ovarian insufficiency, autoimmune gastritis, pernicious anemia, and the
94 same mono-allelic p.C311Y mutation indicating dominant inheritance. With his second
95 partner (I:3), he had four children of whom three carried the mono-allelic p.C311Y mutation
96 and developed various forms autoimmunity; one daughter (II:2) had alopecia areata and nail
97 dystrophy on one of ten finger nails, another daughter (II:4) had hypoparathyroidism, and
98 primary ovarian insufficiency, while a son (II:3) was diagnosed with autoantibodies against
99 tyrosine hydroxylase (often associated with APS-1) (Hedstrand et al., 2000), but otherwise
100 had no autoimmune manifestations (**Figure 1A, Table 1** and Table S1). To exclude autosomal
101 recessive inheritance at the *AIRE* locus, we performed microsatellite markers analysis, which
102 validated that the affected children had indeed inherited different maternal *AIRE* alleles
103 (Figure S1).
104 We next analyzed if p.C311Y can repress the transcription-transactivation potential
105 of WT AIRE in a dominant negative manner. To this end we utilized the human thymic
106 epithelial 4D6 cell line, which was transfected with either WT-*AIRE* and/or mutated *AIRE*
107 expression vectors. We then measured the mRNA expression of a panel of AIRE-dependent
108 (*KRT14*, *S100A8* and *IGFL1*) and –independent genes (*CCNH* and *PRMT3*) (Giraud et al.,
109 2012). As expected, the WT-AIRE induced strong expression of all analyzed AIRE-dependent
110 genes, whereas p.C311Y, p.G228W, p.L28P and the deleterious major Finnish mutation
111 p.R257* did not (**Figure 1B**, Figure S2). No differences among the *WT-AIRE* or *AIRE* mutants
112 were seen for AIRE-independent genes (**Figure 1B**, Figure S2). Strikingly, when 4D6 cells
113 were co-transfected with different ratios of WT-*AIRE* and the above mutants, p.C311Y

114 completely abolished the ability of WT-AIRE to induce expression of AIRE-dependent genes
115 (**Figure 1B**, Figure S2), as did the previously reported SAND domain mutant p.G228W
116 (dominant negative control) (Su et al., 2008). Conversely, neither p.R257* nor the p.L28P
117 CARD mutation showed this inhibiting effect (recessive controls). Taken together, these data
118 validate that the p.C311Y mutant exerts a dominant negative effect on WT AIRE function,
119 both *in vitro* and in human patients.
120
121 **Identification of dominant-negative variants of AIRE**
122 As the phenotype in family A segregated with a heterozygous mutation in *AIRE* with an
123 inhibitory effect on transcription of AIRE-dependent genes, we asked if there might be more
124 dominant *AIRE* mutations. To test this hypothesis we generated a panel of expression
125 vectors with reported disease-causing mutations including several located in the PHD1,
126 CARD, and SAND domains (**Figure 2A**). First we tested the dominant negative effect of AIRE-
127 mutants in co-transfection experiments with WT-AIRE in 4D6 cells. Similarly to the p.C311Y
128 mutation, virtually all missense mutations in the PHD1 finger, including p.E298K, p.V301M,
129 p.C302Y, p.R303P, p.G305S, p.D312N, and p.P326L revealed a dominant negative effect on
130 AIRE-dependent genes (**Figure 2B**, Figure S3, Table S3). Interestingly, the dominant negative
131 effect of p.V301M varied with the downstream gene tested (**Figure 2B**, Figure S3 in the
132 Supplement), which was surprising but reproducible in several independent experiments. In
133 contrast, most of AIRE's CARD mutants, as well as the truncated PHD1-mutant p.C311*
134 revealed a clear recessive pattern, while the common p.C322del13, p.R328Q and p.C446G
135 displayed only a partial dominant effect (**Figure 2B**, Figure S3, Table S3). Conversely, p.R471C
136 (PHD2 domain) had no effect on AIRE-dependent gene transcription (**Figure 2B**, Figure S3,

137 Table S3). As expected, AIRE-independent transcriptional activity was not affected in any of
138 these analyses (**Figure 2B**, Figure S3). This series of experiments demonstrated that the
139 heterozygous mutations in *AIRE* can be segregated into three groups according to their
140 potential to impact on the transcription-transactivation potential of WT AIRE in; (i) dominant
141 negative, (ii) recessive, and (iii) partial dominant negative manners. Moreover, our data
142 revealed that most of the mutations operating in a dominant negative manner are clustered
143 within the PHD1 finger, while most recessive mutations were clustered within the CARD
144 domain.

145

146 **Dominant negative mutants physically co-localize with WT AIRE**

147 To better understand the unique properties of the dominant mutants, we next analyzed
148 their nuclear localization patterns. 4D6 cells were co-transfected with red fluorescent
149 protein (RFP)-tagged WT AIRE plasmids together with expression vectors encoding individual
150 AIRE mutants tagged with enhanced green fluorescent protein (EGFP). Importantly, all
151 dominant mutants, including the PHD1 missense mutations, localized in nuclear speckles
152 typical for WT-AIRE and co-localized with WT-AIRE protein (yellow overlay) (**Figure 3A** and
153 Figure S4, Table S2 and S3). In contrast, recessive CARD mutants (p.L28P, p.LL28_29PP;
154 p.Y90C; p.L97P) which are thought to disrupt AIRE homo-oligomerization (Kumar et al., 2001;
155 Pitkanen et al., 2001), failed to provide the same speckles and stained diffusely throughout
156 the nucleus when transfected alone. In co-transfections, however, all CARD mutants partly
157 co-localized with WT-AIRE, indicating that when co-expressed some functional oligomers are
158 able to form.

159 Since virtually all analyzed PHD1 mutants demonstrated a dominant negative effect,
160 we sought to gain more insights about the impact of these mutants on molecular structure
161 of this domain. Specifically, *in silico* analysis predicted that the p.C311 residue is crucial for
162 chelating Zn^{2+}, and thereby is critical for correct folding of the PHD1 finger. Indeed, a
163 substitution of the cysteine with tyrosine is predicted to disrupt PHD1 folding (Chakravarty
164 et al., 2009) (**Figure 3B**). Additional structural analyses revealed that many of the reported
165 missense mutations changed amino acids that are conserved among different species
166 (Bjorses et al., 2000; Org et al., 2008; Spiliotopoulos et al., 2012) (Figure S5), and can
167 similarly affect the Zn^{2+}-binding or folding of the domain.

168 Taken together, these data suggest that most of the PHD1 mutants can, unlike their
169 CARD mutant counterparts, physically associate with WT AIRE in nuclear speckles and form a
170 homo-oligomer, which is however not functional due to dysfunctional PHD1 fingers.
171

172 **Proof of concept – additional PHD1 dominant-negative AIRE mutations segregate with**
173 **organ-specific autoimmunity**

174 Our *in-vitro* analyses predicted that in addition to the p.C311Y mutation, more dominant
175 mutations are clustered within the PHD1 finger and may therefore similarly cause organ-
176 specific autoimmunity in human patients. To validate this hypothesis, we performed a
177 thorough analysis of patient cohorts available to us. First, we reinvestigated a previously
178 described case, in which p.C311Y had been reported as a compound heterozygous mutation
179 with p.R257* in two Finnish siblings with childhood-onset of APS-1 (Bjorses et al., 2000)
180 (**Table 1**, (Family B, II:3 and II:4), **Figure 4A** and Table S1). Re-sequencing *AIRE* in this family
181 confirmed the earlier report, but also revealed that one of the affected siblings' son (III:1)

182 had inherited p.C311Y, but not p.R257*. He manifested with vitiligo and severe pernicious
183 anemia due to autoimmune gastritis at young age. Moreover, the maternal grandmother
184 (I:2), also a heterozygous p.C311Y carrier, was diagnosed with pernicious anemia and several
185 autoantibodies characteristic of APS-1 (**Table 1, Figure 4A** and Table S1). In contrast, the
186 third daughter (II:1), a heterozygous carrier of p.R257*, was without detectable
187 autoantibodies.

188 Next, we reinvestigated a woman with APS-2 characterized by adrenal insufficiency,
189 autoimmune thyroid disease, primary ovarian insufficiency and autoantibodies characteristic
190 of APS-I with a mono-allelic c.901G>A (p.V301M) mutation (**Table 1** (Family C), **Figure 4A** and
191 Table S1) (Soderbergh et al., 2000). Her daughter also with a p.V301M mutation, had
192 autoantibodies against IL-17F, which are often found in APS-1 patients. However, she did not
193 present with any additional autoimmune manifestations at age 30 years. Finally, additional
194 screening of a large cohort of 85 Russian APS-1 patients and some of their family members
195 identified a young girl with a mono-allelic p.C302Y mutation, who developed
196 hypoparathyroidism and autoantibodies against interferon omega, NALP-5 and 21-
197 hydroxylase (**Table 1 (subject D**). Like p.C311Y, p.C302Y revealed dominant negative effects
198 on AIRE-mediated transcription (**Figure 2B**, Figure S3 and Table S3). A very similar case with
199 a *de novo* mono-allelic p.C302Y mutation was reported by us earlier (Oftedal et al., 2008)
200 (**Table 1** (subject E)).

201 In summary, our data illustrate that individuals with bi-allelic disease-causing *AIRE*
202 mutations develop classic early onset APS-1 phenotypes, while those carrying one of three
203 different mono-allelic mutations in the PHD1 finger (p.C311Y, p.V301M and p.C302Y)
204 segregate with clear, but varying autoimmune phenotypes, ranging from late-onset classical

205 APS-1 (e.g. I:3, Figure 1A), to APS-2 (**Table 1, Figure 4B** and Table S1), and isolated organ-
206 specific autoimmunity (e.g. vitiligo, PA, and APS-1-specific auto-antibodies).
207

208 **Increased frequency of dominant PHD1 mutations in various forms of organ-specific**
209 **autoimmunity**

210 The above findings raised the question whether dominant PHD1 mutations could generally
211 cause organ-specific autoimmunity. To answer this question, we sequenced the full exon 8
212 (encoding the PHD1 finger) in several autoimmune patients and controls available to us from
213 our national registry. We first analyzed the presence of PHD1 mutants in familial cases
214 characterized by the presence of adrenal insufficiency, autoimmune thyroid disease and/or
215 type 1 diabetes (i.e. APS-2 and /or APS-3). Indeed, among 41 such families, we identified one
216 family with three family members bearing a mono-allelic c.977C>T (p.P326L) mutation (**Table**
217 **1** (Family F), **Figure 4A** and Table S1). The mother (II:3) was diagnosed with autoimmune
218 thyroid disease, adrenal insufficiency, pernicious anemia and vitiligo. Her children both
219 acquired vitiligo at 10 (III:1) and 7 (III:2) years of age, respectively.

220 Furthermore, since pernicious anemia, vitamin B12 deficiency, and/or vitiligo seemed
221 to be often associated with heterozygous PHD1 mutations in previous cases (**Figure 4B**), we
222 next screened large cohorts of patients with these conditions. Among 177 probands and 26
223 affected relatives with pernicious anemia, we identified several dominant negative PHD1
224 mutants; First, a patient with a heterozygous c.913G>A (p.G305S) mutation who was
225 intrinsic factor (IF) antibody positive and developed severe anemia and neuropathy at age 43
226 (**Table 1,** (Family G), Figure 4A and Table S1). Her mother (II:2) and maternal grandmother
227 (III:2) were reported to have pernicious anemia, the mother also suffered from

228 hypothyroidism and cirrhosis. p.G305S is close to the zinc binding site and predictably
229 disrupts the zinc finger structure. Not surprisingly, the dominant negative effect on gene
230 transcription was evident (**Figure 2B,** Figure S3 and Table S3). Another patient in this cohort
231 developed intrinsic factor antibody positive pernicious anemia at age 81 years and was
232 heterozygous for both c.946C>T (p.R316W) and the common c.967-979del13bp
233 (p.C322del13) mutation on the same allele (**Table 1** and Table S1 (subject H)). Both p.R316W
234 and (p.C322del13) were predicted to have a partial dominant negative effect.
235 Similarly, among 170 patients with isolated and familial (n=64) vitiligo, a female who
236 developed acrofacial vitiligo at age 21 years, with gastric parietal cell autoantibodies, low
237 normal serum vitamin B12 level , and a heterozygous mutation in c.983G>A (p.R328Q) (**Table**
238 **1** (subject I) and Table S1). Like p.P326L, a mutation in this C-terminal part of PHD1 does not
239 disrupt the histone binding site, but still displays an incomplete inhibition of AIRE-dependent
240 gene transcription (**Figure 2B,** Figure S3 and Table S3). *AIRE* sequencing revealed that the
241 patient also had p.V484A; a sequence variant that has been described in a patient with
242 alopecia and nail dystrophy (Buzi et al., 2003). We were unfortunately unable to perform an
243 allele discrimination assay in this patient.
244 Importantly, sequencing of 450 control blood donors did not reveal presence of any
245 of the dominant negative PHD1 mutations, demonstrating that dominant PHD1 mutations
246 are clearly over-represented among patients suffering from various forms of organ-specific
247 autoimmunity.
248

249 The frequency of dominant negative PHD1 AIRE mutations in populations

250 To better estimate the frequency of some of the dominant negative PHD1 AIRE mutations,
251 we analyzed multiple exome chip datasets that were available, containing some of the PHD1
252 *AIRE* sequence variations. Specifically, sequence analysis from existing exome chip datasets
253 from a total of 1670 Scandinavian individuals (healthy controls (n=637), and patients with
254 attention deficit (n= 589) or movement disorders (n=444)), we determined the minor allele
255 frequency of p.V301M to be 0.00089 (i.e 3 out of 1667 persons), while other covered
256 mutations p.G303S, p.R303Q, and p.R257* were not found. The relatively high frequency of
257 the p.V301M dominant mutant was further validated by additional datasets obtained from
258 public databases, including the recently published data from The Broad Institute (covering
259 over 60 thousand individuals) (Exome Aggregation Consortium (ExAC), Cambridge, MA
260 (URL: http://exac.broadinstitute.org)), 1000 Genome database
261 (http://www.1000genomes.org) and the Washington Database (~6 thousand individuals)
262 (Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL:
263 http://evs.gs.washington.edu/EVS/). All above databases confirmed and broadened these
264 findings and demonstrated that dominant-negative PHD1-mutations are present with minor
265 allele frequency reaching 0.0009 (mainly p.V301M and p.R303Q) (**Table 2**). It should be
266 stressed however, that most of the dominant negative PHD1 variants were not covered on
267 these exom chips, suggesting that the actual frequency may be even higher.
268

269 ## DISCUSSION

270 ### Molecular aspects of dominant-negative mutations of AIRE

271 Many proteins are active only in the form of a multimeric complex, composed of two
272 or more copies of the same protein. It is well established that in many of these cases, mono-

273 allelic mutations can completely or partially disrupt the structure and thereby the activity of
274 the entire multimeric complex in a dominant-negative manner. Since AIRE was shown to
275 form a homo-tetramer *in vivo* (Kumar et al., 2001), it is rather surprising that only one mono-
276 allelic mutation in the *AIRE* locus has been linked to APS-1 and/or other forms of organ-
277 specific autoimmune disorders so far. We identify several novel heterozygous missense
278 mutations in *AIRE*, primarily clustered within its PHD1 zinc finger (**Figure 4B**), which are
279 characterized by dominant inheritance, later debut, milder phenotypes, and reduced
280 penetrance. Interestingly, most autosomal recessive missense mutations causing APS-1 are
281 predominantly found within the CARD domain (Bjorses et al., 2000), suggesting that the
282 recessive or dominant character of the given mutation is, to a large extent, determined by its
283 position within the AIRE protein. This likely reflects the different and unique roles of the
284 individual domains of the AIRE protein. Specifically, while the CARD domain has been shown
285 to be critical for AIRE homo-oligomerization and speckled nuclear localization (Bjorses et al.,
286 1999; Kumar et al., 2001), the PHD domain of AIRE functions as an epigenetic reader,
287 specifically recognizing unmethylated lysine 4 on histone 3 (H3K4me0) (Org et al., 2008). The
288 PHD1 domain was shown to be absolutely critical for AIRE's transcription-transctivation
289 activity, as well as for its capacity to prevent multiorgan autoimmunity in transgenic mouse
290 models (Bjorses et al., 2000; Koh et al., 2010; Koh et al., 2008). *In silico* simulations revealed
291 that the PHD1 residues N295-C310 are important in the intermolecular interactions with
292 histone H3 residues (**Figure 2B,** Figure 3B and Table S3). PHD1 is unable to interact with
293 H3K4me0 if the zinc chelating cysteines are mutated, as is the case for C311Y (Bottomley et
294 al., 2005). The formation of salt-bridges between the side chains of H3 residue R2 and D312
295 was shown to be crucial for binding specificity (Koh et al., 2008), explaining why the

296 structure is highly conserved in AIRE among different species and also in PHD-zinc finger
297 domain-containing proteins (Figure S5).
298 Unlike the PHD1 mutants, mutations clustered within the CARD domain of AIRE do
299 not exert any dominant negative effect (**Figure 2B,** Figure S3 and Table S3). In homozygotes
300 these mutations impact on AIRE oligomerization and correct nuclear localization (Bjorses et
301 al., 1999; Kumar et al., 2001; Pitkanen et al., 2001), yet may be able to form oligomers when
302 expressed along with WT AIRE (**Figure 3A,** Figure S4 and Table S2). Interestingly, truncating
303 AIRE mutations such as p.R257* and p.C311* also behave in a recessive manner, in spite of
304 their ability to co-localize and interact with WT-AIRE (**Figure 3A**, Figure S4 and Table S2). This
305 suggests that the above truncations do not disrupt the core structure of the AIRE complex,
306 necessary for its biological activity. Such core structure likely involves formation of functional
307 dimers within the truncated tetramer (**Figure 5A**).
308 It is therefore not entirely surprising that mono-allelic and dominant negative
309 mutations in this domain will impact on the structure and thus the activity of the entire AIRE
310 tetramer. However, such dominant effect seems to follow incomplete inheritance, as most
311 of the patients develop milder phenotypes with later onset compared to patients with
312 classical, autosomal recessive APS1. This could be because the AIRE tetramers still have
313 some residual activity, and/or that some pure WT-AIRE tetramers are still formed and are
314 sufficient to induce some level of self-tolerance. Moreover, the extent of the dominant
315 effect seems to depend on which residue is mutated. Our results suggest that mutations in
316 residues 302 and 311 resemble more classical APS-1 than other mutations, although we
317 observed large diversity within the two families with p.C311Y studied here.
318

319 ## Clinical aspects of dominant-negative mutations of AIRE

320 The genetic contribution of *AIRE* to other autoimmune diseases than APS-1 has been
321 studied by us and others, but in most cases only SNPs or a few common mutations have
322 been analyzed, thereby overlooking rare mutations or large deletions (Jin et al., 2007; Pforr
323 et al., 2006; Thomson et al., 2007; Torok et al., 2004; Turunen et al., 2006; Vaidya et al.,
324 2000). Although some heterozygous mutations in *AIRE* have been associated with
325 autoimmunity in single patients (Table S4), a dominant negative effect on AIRE function was
326 not considered in these cases. Here, we demonstrate for the first time that the heterozygous
327 variants observed in the families as well as other mutations analyzed within AIRE exon 8
328 have an inhibitory effect on AIRE-mediated transcription. This contrasts to classical APS-1
329 with recessive inheritance and early presentation (mean age 9.1 years (Wolff et al., 2007a));
330 90% develops all three components by age 20 years (Wolff et al., 2007a), Organ-specific
331 autoimmunity in the heterozygous cases presents later (mean age 24.4 years, n = 12),
332 progresses more slowly, fewer patients develop the diagnostic dyad, and the penetrance is
333 incomplete (**Figures 4B and 5B**). This is reminiscent of autoimmune lymphoproliferative
334 syndrome, which shows 60 % penetrance among family members harboring the same
335 heterozygous gene mutation (Price et al., 2014), or to the incomplete penetrance seen in
336 families carrying heterozygous CTLA4 mutations (Kuehn et al., 2014). More importantly, the
337 unusual heterozygous cases may not even be recognized as APS-1 as many patients
338 masquerade as common types of organ-specific autoimmunity in one or several organs.
339 Thus, the original classification of APS-1 as a strictly autosomal recessive disease (with one
340 exception (Cetani et al., 2001)) is obsolete. Instead, we propose that APS-1 exists in two
341 forms: (i) 'classical', characterized by recessive inheritance, presence of at least two of three

342 main components, and interferon antibodies; and (ii) 'non-classical', characterized by
343 dominant heterozygous mutations mainly in AIRE's PHD1 zinc finger and a milder less
344 penetrant autoimmune phenotype (**Figure 5B**). Families with dominant clustering of organ-
345 specific autoimmunity, especially when pernicious anemia and / or vitiligo manifests at early
346 age, might have such mutations, although the clinical phenotype might be expanded when
347 larger materials are investigated. Furthermore, it is reasonable to assume that mutation
348 carriers have a significant risk for polyendocrinopathy, which should be reflected in their
349 follow-up programs. Moreover, autoantibodies against interferons, hallmarks of classical
350 APS-1, are much less prevalent in the non-classical form probably reflecting some residual
351 AIRE-function at least for some of the PHD1 mutations.

352 Since deep DNA sequencing of thousands of different patients was beyond the scope
353 of the current study, we cannot provide accurate estimates of the prevalence of non-
354 classical APS-1 since a population cohort with autoimmune phenotypes was not available.
355 Based on our own data and publicly available databases representing patients with diverse
356 conditions in different ethnic groups, a conservative estimate puts dominant *AIRE* mutations
357 at a genotype frequency of 1-2 persons per thousand, not restricted to the Scandinavian
358 population as also is underpinned by literature reports (Cervato et al., 2010; Ferrera et al.,
359 2007; Stolarski et al., 2006; Vogel et al., 2001) (**Table 2** and Table S4). However, further
360 studies are needed to establish the prevalence and risk associated with mutations in the
361 PHD1 domain in larger populations.

362 In conclusion, this study represents the first demonstration that *AIRE* mutations
363 associate with common organ-specific autoimmunity with a variable phenotype ranging
364 from classical APS-1 to a non-classical form that mimics common organ-specific

365 autoimmunity. Finally, our study provides important insights into the molecular mode of
366 action of the AIRE protein and highlights unique structural properties that are required for
367 AIRE's biological activity.
368

369 **EXPERIMENTAL PROCEDURES**

370 **Patients**

371 Norwegian, Finnish, and Russian patients were recruited from the respective national patient
372 registries and biobanks of patients with APS-1, adrenal insufficiency and polyendocrine syndromes.
373 Vitiligo patients were recruited by the Sheffield Teaching Hospitals NHS Trust, Sheffield, UK;
374 pernicious anaemia patients were recruited by Manchester Centre for Genomic Medicine, Central
375 Manchester University Hospitals NHS Trust in collaboration with the Pernicious Anaemia Society of
376 United Kingdom. For estimation of population frequencies of AIRE mutations, exome chip data from
377 cohorts with healthy controls (n=637), and patients groups without known susceptibility for
378 autoimmunity were available (for details, see Supplemental Methods). All participating patients
379 signed an informed consent. Samples from blood donors were recruited from the Haukeland
380 University Hospital blood bank. The study was approved by the Regional Ethics committees in each
381 institution.

382

383 ***AIRE* sequencing, copy number analysis and microsatellite typing**

384 All 14 exons of the *AIRE* gene (EMBL acc. Number AJ009610) were amplified by PCR and sequenced
385 as described previously (Wolff et al., 2007b). The PHD1 zinc finger is encoded by exon 8 (see
386 Supplemental Methods). Copy number analysis was performed by duplex TaqMan real-time PCR
387 assay (Boe Wolff et al., 2008). Microsatellite typing of the *AIRE* region was performed according to
388 Myhre *et al* (Myhre et al., 2004). The samples used to estimate population frequencies for *AIRE*
389 mutations were genotyped on the HumanExome 12v1_B (ADHD study) and HumanCoreExome 12v1-

390 1 (movement disorders study) Bead chips respectively (Illumina Inc, San Diego, CA). For further
391 information and analysis of data see Supplemental Methods in the Supplement.
392
393 **Assay of autoantibodies**
394 Autoantibodies typical of APS-1, were assayed by radioligand binding assays as previously described
395 (Husebye et al., 1997; Oftedal et al., 2008) (Supplemental Methods).
396
397 **Assay of AIRE-regulated genes**
398 The human 4D6 thymic epithelial cell line was transfected with AIRE-containing plasmid constructs
399 using the Fugene HD transfection reagent (Promega Corporation, Madison, WI, USA) according to the
400 manufacturers' protocol. Mutations in *AIRE* were engineered using site-directed mutagenesis
401 (Supplemental Methods). Genes previously shown to be regulated by AIRE (Abramson et al., 2010)
402 were analyzed by quantitative PCR, and the comparative Ct-method (Applied Biosystems, Carlsbad,
403 CA, USA) (SupplementalMethods).
404
405 **Immunofluorescence**
406 4D6 cells were grown on sterile coverslips and transfected with EGFP-AIRE and/or RFP-AIRE fusion
407 plasmids using Fugene HD transfection reagent, and analyzed under a Zeiss LSM 510 META Laser
408 Scanning confocal microscope (Supplemental Methods).
409
410 **Structure modelling**
411 Sequence alignment was made using Clustal Omega Multiple sequence alignment tool
412 (http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalo). Modelling of PHD1 was
413 performed using PyMOL and the coordinates of the PDB entry 1XWH (Bottomley et al., 2005).
414

415 SUPPLEMENTAL INFORMATION

416 Supplemental information includes supplemental methods, Supplemental figures S1-S5,

417 Supplemental table S1-S5.

418

419 **AUTHOR CONTRIBUTIONS**

420 BEO, AH, ASBW, EB and AV performed the experiments. MKV did the HLA genotyping and SJF did the

421 in-silico analysis and structural modelling. TF and PMK provided the gen-analysis and microsatellite

422 typing of the *AIRE* region, and KH, TZ and SJ provided the genetic frequency data. MMA, JP, EHK,

423 APW, SB, WGN, WACS, LSS, EMO, KL, and ESH provided samples and clinical data for the patients.

424 BEO, JA and EH coordinated the study and wrote the manuscript. All authors discussed the results

425 and commented on the manuscript.

426

427 **ACKNOWLEDGEMENT**

428 This study was supported by grants from The Regional Health Authorities of Western

429 Norway, The Norwegian Research Council, The Israel Science Foundation (JA, SJF), Bergen

430 Medical Research Foundation (ASBW) and Nils Norman's Traveling Fund in Endocrinology

431 (AH). BEO and ESH had full access to all of the data in the study and take responsibility for

432 the integrity of the data and the accuracy of the data analysis. The authors declare no

433 conflict of interest. Technical help from Hajirah Muneer, Elin Theodorsen and Elisabeth

434 Halvorsen is greatly acknowledged. We also thank all the patient participants and physicians

435 of The National Registry of Organ-specific Autoimmune Diseases (Drs Anne-Grethe Myhre,

436 Johan Svartberg, Kristian Fougner, Anders Jørgensen, Tore Julsrud Berg, Kari Lima, Bjarne

437 Mella, Bjørn Nedrebø, and Siri Carlsen) for collection of clinical information. We would like

438 to thank Dr Vinod Devalia, Princess of Wales Hospital, and Professor Mark Pritchard,

439 University of Liverpool for collecting pernicious anemia samples. Professor Christophe
440 Benoist, Harvard Medical School is thanked for generously providing human thymic 4D6
441 cells. The authors would like to thank the NHLBI GO Exome Sequencing Project and its
442 ongoing studies which produced and provided exome variant calls for comparison: the Lung
443 GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO
444 Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926) and the
445 Heart GO Sequencing Project (HL-103010).

446

447 **REFERENCES**

448 Abramson, J., Giraud, M., Benoist, C., and Mathis, D. (2010). Aire's partners in the molecular control
449 of immunological tolerance. Cell *140*, 123-135.
450 Ahonen, P., Myllarniemi, S., Sipila, I., and Perheentupa, J. (1990). Clinical variation of autoimmune
451 polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J
452 Med *322*, 1829-1836.
453 Bjorses, P., Halonen, M., Palvimo, J.J., Kolmer, M., Aaltonen, J., Ellonen, P., Perheentupa, J., Ulmanen,
454 I., and Peltonen, L. (2000). Mutations in the AIRE gene: effects on subcellular location and
455 transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy
456 protein. Am J Hum Genet *66*, 378-392.
457 Bjorses, P., Pelto-Huikko, M., Kaukonen, J., Aaltonen, J., Peltonen, L., and Ulmanen, I. (1999).
458 Localization of the APECED protein in distinct nuclear structures. Hum Mol Genet *8*, 259-266.
459 Boe Wolff, A.S., Oftedal, B., Johansson, S., Bruland, O., Lovas, K., Meager, A., Pedersen, C., Husebye,
460 E.S., and Knappskog, P.M. (2008). AIRE variations in Addison's disease and autoimmune
461 polyendocrine syndromes (APS): partial gene deletions contribute to APS I. Genes Immun *9*, 130-136.
462 Bottomley, M.J., Stier, G., Pennacchini, D., Legube, G., Simon, B., Akhtar, A., Sattler, M., and Musco,
463 G. (2005). NMR structure of the first PHD finger of autoimmune regulator protein (AIRE1). Insights
464 into autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) disease. J Biol
465 Chem *280*, 11505-11512.
466 Buzi, F., Badolato, R., Mazza, C., Giliani, S., Notarangelo, L.D., Radetti, G., and Plebani, A. (2003).
467 Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review
468 diagnostic criteria? J Clin Endocrinol Metab *88*, 3146-3148.
469 Cervato, S., Morlin, L., Albergoni, M.P., Masiero, S., Greggio, N., Meossi, C., Chen, S., del Pilar Larosa,
470 M., Furmaniak, J., Rees Smith, B.*, et al.* (2010). AIRE gene mutations and autoantibodies to interferon
471 omega in patients with chronic hypoparathyroidism without APECED. Clin Endocrinol (Oxf) *73*, 630-
472 636.
473 Cetani, F., Barbesino, G., Borsari, S., Pardi, E., Cianferotti, L., Pinchera, A., and Marcocci, C. (2001). A
474 novel mutation of the autoimmune regulator gene in an Italian kindred with autoimmune
475 polyendocrinopathy-candidiasis-ectodermal dystrophy, acting in a dominant fashion and strongly
476 cosegregating with hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab *86*, 4747-4752.
477 Chakravarty, S., Zeng, L., and Zhou, M.M. (2009). Structure and site-specific recognition of histone H3
478 by the PHD finger of human autoimmune regulator. Structure *17*, 670-679.
479 Cowan, J.E., Parnell, S.M., Nakamura, K., Caamano, J.H., Lane, P.J., Jenkinson, E.J., Jenkinson, W.E.,
480 and Anderson, G. (2013). The thymic medulla is required for Foxp3+ regulatory but not conventional
481 CD4+ thymocyte development. J Exp Med *210*, 675-681.
482 Ferguson, B.J., Alexander, C., Rossi, S.W., Liiv, I., Rebane, A., Worth, C.L., Wong, J., Laan, M.,
483 Peterson, P., Jenkinson, E.J.*, et al.* (2008). AIRE's CARD revealed, a new structure for central tolerance
484 provokes transcriptional plasticity. J Biol Chem *283*, 1723-1731.
485 Ferrera, F., Rizzi, M., Sprecacenere, B., Balestra, P., Sessarego, M., Di Carlo, A., Filaci, G., Gabrielli, A.,
486 Ravazzolo, R., and Indiveri, F. (2007). AIRE gene polymorphisms in systemic sclerosis associated with
487 autoimmune thyroiditis. Clin Immunol *122*, 13-17.
488 Gardner, J.M., Devoss, J.J., Friedman, R.S., Wong, D.J., Tan, Y.X., Zhou, X., Johannes, K.P., Su, M.A.,
489 Chang, H.Y., Krummel, M.F., and Anderson, M.S. (2008). Deletional tolerance mediated by
490 extrathymic Aire-expressing cells. Science *321*, 843-847.
491 Giraud, M., Yoshida, H., Abramson, J., Rahl, P.B., Young, R.A., Mathis, D., and Benoist, C. (2012). Aire
492 unleashes stalled RNA polymerase to induce ectopic gene expression in thymic epithelial cells. Proc
493 Natl Acad Sci U S A *109*, 535-540.
494 Hedstrand, H., Ekwall, O., Haavik, J., Landgren, E., Betterle, C., Perheentupa, J., Gustafsson, J.,
495 Husebye, E., Rorsman, F., and Kampe, O. (2000). Identification of tyrosine hydroxylase as an

496 autoantigen in autoimmune polyendocrine syndrome type I. Biochem Biophys Res Commun *267*,
497 456-461.
498 Husebye, E.S., and Anderson, M.S. (2010). Autoimmune polyendocrine syndromes: clues to type 1
499 diabetes pathogenesis. Immunity *32*, 479-487.
500 Husebye, E.S., Gebre-Medhin, G., Tuomi, T., Perheentupa, J., Landin-Olsson, M., Gustafsson, J.,
501 Rorsman, F., and Kampe, O. (1997). Autoantibodies against aromatic L-amino acid decarboxylase in
502 autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab *82*, 147-150.
503 Jin, Y., Bennett, D.C., Amadi-Myers, A., Holland, P., Riccardi, S.L., Gowan, K., Fain, P.R., and Spritz,
504 R.A. (2007). Vitiligo-associated multiple autoimmune disease is not associated with genetic variation
505 in AIRE. Pigment Cell Res *20*, 402-404.
506 Koh, A.S., Kingston, R.E., Benoist, C., and Mathis, D. (2010). Global relevance of Aire binding to
507 hypomethylated lysine-4 of histone-3. Proc Natl Acad Sci U S A *107*, 13016-13021.
508 Koh, A.S., Kuo, A.J., Park, S.Y., Cheung, P., Abramson, J., Bua, D., Carney, D., Shoelson, S.E., Gozani, O.,
509 Kingston, R.E.*, et al.* (2008). Aire employs a histone-binding module to mediate immunological
510 tolerance, linking chromatin regulation with organ-specific autoimmunity. Proc Natl Acad Sci U S A
511 *105*, 15878-15883.
512 Kuehn, H.S., Ouyang, W., Lo, B., Deenick, E.K., Niemela, J.E., Avery, D.T., Schickel, J.N., Tran, D.Q.,
513 Stoddard, J., Zhang, Y.*, et al.* (2014). Immune dysregulation in human subjects with heterozygous
514 germline mutations in CTLA4. Science *345*, 1623-1627.
515 Kumar, P.G., Laloraya, M., Wang, C.Y., Ruan, Q.G., Davoodi-Semiromi, A., Kao, K.J., and She, J.X.
516 (2001). The autoimmune regulator (AIRE) is a DNA-binding protein. J Biol Chem *276*, 41357-41364.
517 Meager, A., Visvalingam, K., Peterson, P., Moll, K., Murumagi, A., Krohn, K., Eskelin, P., Perheentupa,
518 J., Husebye, E., Kadota, Y., and Willcox, N. (2006). Anti-interferon autoantibodies in autoimmune
519 polyendocrinopathy syndrome type 1. PLoS Med *3*, e289.
520 Myhre, A.G., Stray-Pedersen, A., Spangen, S., Eide, E., Veimo, D., Knappskog, P.M., Abrahamsen, T.G.,
521 and Husebye, E.S. (2004). Chronic mucocutaneous candidiasis and primary hypothyroidism in two
522 families. Eur J Pediatr *163*, 604-611.
523 Oftedal, B.E., Wolff, A.S., Bratland, E., Kampe, O., Perheentupa, J., Myhre, A.G., Meager, A.,
524 Purushothaman, R., Ten, S., and Husebye, E.S. (2008). Radioimmunoassay for autoantibodies against
525 interferon omega; its use in the diagnosis of autoimmune polyendocrine syndrome type I. Clin
526 Immunol *129*, 163-169.
527 Org, T., Chignola, F., Hetenyi, C., Gaetani, M., Rebane, A., Liiv, I., Maran, U., Mollica, L., Bottomley,
528 M.J., Musco, G., and Peterson, P. (2008). The autoimmune regulator PHD finger binds to non-
529 methylated histone H3K4 to activate gene expression. EMBO Rep *9*, 370-376.
530 Perheentupa, J. (2006). Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. J Clin
531 Endocrinol Metab *91*, 2843-2850.
532 Pforr, J., Blaumeiser, B., Becker, T., Freudenberg-Hua, Y., Hanneken, S., Eigelshoven, S., Cuyt, I., De
533 Weert, J., Lambert, J., Kruse, R.*, et al.* (2006). Investigation of the p.Ser278Arg polymorphism of the
534 autoimmune regulator (AIRE) gene in alopecia areata. Tissue Antigens *68*, 58-61.
535 Pitkanen, J., Doucas, V., Sternsdorf, T., Nakajima, T., Aratani, S., Jensen, K., Will, H., Vahamurto, P.,
536 Ollila, J., Vihinen, M.*, et al.* (2000). The autoimmune regulator protein has transcriptional
537 transactivating properties and interacts with the common coactivator CREB-binding protein. J Biol
538 Chem *275*, 16802-16809.
539 Pitkanen, J., Vahamurto, P., Krohn, K., and Peterson, P. (2001). Subcellular localization of the
540 autoimmune regulator protein. characterization of nuclear targeting and transcriptional activation
541 domain. J Biol Chem *276*, 19597-19602.
542 Price, S., Shaw, P.A., Seitz, A., Joshi, G., Davis, J., Niemela, J.E., Perkins, K., Hornung, R.L., Folio, L.,
543 Rosenberg, P.S.*, et al.* (2014). Natural history of autoimmune lymphoproliferative syndrome
544 associated with FAS gene mutations. Blood *123*, 1989-1999.

545 Soderbergh, A., Rorsman, F., Halonen, M., Ekwall, O., Bjorses, P., Kampe, O., and Husebye, E.S.
546 (2000). Autoantibodies against aromatic L-amino acid decarboxylase identifies a subgroup of patients
547 with Addison's disease. J Clin Endocrinol Metab *85*, 460-463.
548 Spiliotopoulos, D., Spitaleri, A., and Musco, G. (2012). Exploring PHD Fingers and H3K4me0
549 Interactions with Molecular Dynamics Simulations and Binding Free Energy Calculations: AIRE-PHD1,
550 a Comparative Study. PLoS One *7*, e46902.
551 Stolarski, B., Pronicka, E., Korniszewski, L., Pollak, A., Kostrzewa, G., Rowinska, E., Wlodarski, P.,
552 Skorka, A., Gremida, M., Krajewski, P., and Ploski, R. (2006). Molecular background of
553 polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome in a Polish population: novel AIRE
554 mutations and an estimate of disease prevalence. Clin Genet *70*, 348-354.
555 Su, M.A., Giang, K., Zumer, K., Jiang, H., Oven, I., Rinn, J.L., Devoss, J.J., Johannes, K.P., Lu, W.,
556 Gardner, J.*, et al.* (2008). Mechanisms of an autoimmunity syndrome in mice caused by a dominant
557 mutation in Aire. J Clin Invest *118*, 1712-1726.
558 Taniguchi, R.T., and Anderson, M.S. (2011). The role of Aire in clonal selection. Immunol Cell Biol *89*,
559 40-44.
560 Thomson, W., Barton, A., Ke, X., Eyre, S., Hinks, A., Bowes, J., Donn, R., Symmons, D., Hider, S., Bruce,
561 I.N.*, et al.* (2007). Rheumatoid arthritis association at 6q23. Nat Genet *39*, 1431-1433.
562 Torok, H.P., Tonenchi, L., Glas, J., Schiemann, U., and Folwaczny, C. (2004). No significant association
563 between mutations in exons 6 and 8 of the autoimmune regulator (AIRE) gene and inflammatory
564 bowel disease. Eur J Immunogenet *31*, 83-86.
565 Turunen, J.A., Wessman, M., Forsblom, C., Kilpikari, R., Parkkonen, M., Pontynen, N., Ilmarinen, T.,
566 Ulmanen, I., Peltonen, L., and Groop, P.H. (2006). Association analysis of the AIRE and insulin genes in
567 Finnish type 1 diabetic patients. Immunogenetics *58*, 331-338.
568 Vaidya, B., Imrie, H., Geatch, D.R., Perros, P., Ball, S.G., Baylis, P.H., Carr, D., Hurel, S.J., James, R.A.,
569 Kelly, W.F.*, et al.* (2000). Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and
570 autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. J Clin Endocrinol
571 Metab *85*, 688-691.
572 Vogel, A., Liermann, H., Harms, A., Strassburg, C.P., Manns, M.P., and Obermayer-Straub, P. (2001).
573 Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and
574 hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology *33*, 1047-1052.
575 Wolff, A.S., Erichsen, M.M., Meager, A., Magitta, N.F., Myhre, A.G., Bollerslev, J., Fougner, K.J., Lima,
576 K., Knappskog, P.M., and Husebye, E.S. (2007a). Autoimmune polyendocrine syndrome type 1 in
577 Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator
578 gene. J Clin Endocrinol Metab *92*, 595-603.
579 Wolff, A.S., Erichsen, M.M., Meager, A., Magitta, N.F., Myhre, A.G., Bollerslev, J., Fougner, K.J., Lima,
580 K., Knappskog, P.M., and Husebye, E.S. (2007b). Autoimmune polyendocrine syndrome type 1 in
581 Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator
582 gene. J Clin Endocrinol Metab *92*, 595-603.

583

584 **Figure 1. APS-1 family with dominant inheritance**. (**A**) Pedigree showing the North-

585 African/Norwegian family with the dominantly inherited p.C311Y mutation. The lover panel

586 show the heterozygous mutation in exon 8 revealed by Sanger sequencing.

587 (**C**)Transcriptional regulation by *WT AIRE* and the different mutations. The AIRE-regulated

588 gene keratin 14 *(KRT14)* was tested together with the AIRE-independent gene cyclin H

589 (*CCNH*) and normalized against the endogenous control beta$_2$-microglobulin (*B2M*). Cells

590 were transfected with various amounts of WT AIRE and mutants, alone or in combinations.

591 The results are shown as fold difference (FD) compared to cells transfected only with WT

592 AIRE (dotted line), error bars are representing SEM.

593

594 **Figure 2. Heterozygous mutations in AIRE and the effect on gene regulation.** (**A**) Model of

595 the AIRE protein with domains and common mutations classified as recessive (black) and

596 dominant (red). (**B**). The AIRE-regulated gene *KRT14* (red bars), and *CCNH* not regulated by

597 AIRE (blue bars). Transcriptional regulation by *WT-AIRE* and mutants was performed as

598 described in Figure 1B. The results are shown as fold difference (FD) compared to cells

599 transfected only with WT AIRE (dotted line), error bars are representing SEM.

600

601 **Figure 3. Subcellular co-localization of the mono-allelic variants. (A)** Confocal fluorescence

602 images displaying the subcellular localization of WT-RFP-AIRE (red) and mutant-EGFP-AIRE

603 (green) constructs. Overlay images shows the degree of co-localization (yellow). Nuclei were

604 visualized with DAPI counterstain (blue). (B) The solution structure of the PHD1 domain of

605 AIRE, showing the Zn^{2+} –ligating residues. Zn^{2+} shown as sphere, and cysteines as sticks. The

606 C311 mutation hotspot is shown in cyan (right). Modelling shows that the C311Y mutation
607 would disrupt Zn^{2+} ligation.
608
609 **Figure 4. The AIRE PHD1-domain**. (**A**) Pedigrees of families with p.C311Y (Family B),
610 p.V301M (Family C) p.P326L (Family F) and p.G305S (Family G) AIRE mutations. (**B**) The AIRE
611 protein with its different domains. The mutations investigated in this study are shown, now
612 color-coded for dominant (red) and recessive (black). The AIRE PHD1 is shown, together with
613 cake diagrams each representing one patient depicting clinical manifestations and
614 autoantibodies.
615
616 **Figure 5. Dominant mutations in AIRE and organ-specific autoimmunity.** (**A**) Schematic
617 illustration of recessive and dominant *AIRE* mutations. The homozygous R257* truncated
618 protein can form oligomers, but they lack critical domains. In the heterozygous state R257*
619 does not interfere with WT-AIRE. PHD1 mutants can form oligomers but AIRE lack
620 transcriptional activity due to its putative interaction with WT-AIRE. Formation of a small
621 fraction of WT:WT oligomers may account for some induction of tolerance and a milder
622 autoimmune phenotype. (**B**) Manifestations and autoantibodies in patients with recessive
623 (from references (Meager et al., 2006; Perheentupa, 2006; Wolff et al., 2007a)) and
624 dominant (this study) mutations. AI, adrenocortical insufficiency; CMC, chronic
625 mucocutaneous candidiasis; HP, hypoparathyroidism; PA, pernicious anemia; V, vitiligo; n.a.,
626 data not available.

Table 1. Families with heterozygous mutations in the *AIRE* gene, their manifestations and autoantibodies

[a]Family	Patient	YoB	Mutation	[b]Manifestations	[c]Organ-specific autoantibodies	[d]Cytokine autoantibodies	[e]HLA class II genotypes stratified to AI risk
A	I:2	1951	p.C311Y;WT	**CMC**, **AI**, PA, PDI, EH	SCC	IFN-ω, IFN-α2	Neutral
	II:1	1971	p.C311Y;WT	**HP**, PA, EH, POI	NALP-5	IFN-ω, IFN-α2	Protective
	II:2	1988	p.C311Y;WT	AA, nail dystrophy		IFN-ω, IFN-α2	Neutral
	II:3	1990	p.C311Y;WT		TH		Protective
	II:4	1995	p.C311Y;WT	**HP**, POI	NALP-5	IFN-ω, IFN-α2	Neutral
	II:5	1998	WT;WT				Protective
B	I:2	1928	p.C311Y;WT	PA, Blind, T2D	21-OH, NALP-5, AADC, IF		Neutral
	II:1	1959	p.R257*;WT	L, oral cancer			Protective
	II:3	1961	p.C311Y;p.R257*	**CMC**, **AI**, POI, A	21-OH, SCC, 17-0H, AADC, TH	IFN-ω, IFN-α2, IL-17F, IL-22	Protective
	II:4	1965	p.C311Y;p.R257*	**HP**, **CMC**, **AI**, POI, A	21-OH, SCC, 17-OH, TPH-1, NALP-5	IFN-ω, IFN-α2, IL-17F, IL-22	Protective
	III:1	1984	p.C311Y;WT	PA, V	GPCA, IF		Neutral
C	I:2	1955	p.V301M;WT	**AI**, AT, POI	21-OH, AADC[f]	IL-17F	Very High

	II:1	1977	WT;WT		n.a	n.a	n.a.
	II:2	1980	p.V301M;WT			IL-17F	Neutral
D		2010	p.C302Y;WT	**HP**	21-OH, NALP-5	IFN- ω	n.a
E		2001	p.C302Y;WT	**HP**	NALP-5	IFN-ω	n.a.
F	I:1	1935	p.P326L;WT				Neutral
	I:2	1943	p.P326L;WT				Neutral
	I:3	1943	WT;WT				Intermediate
	I:4	1944	p.P326L;WT	Low B12	GPCA		High
	II:1	1967	p.P326L;WT				Intermediate
	II:3	1972	p.P326L;WT	**AI**, PA, V, hypothyroidism	21-OH		High
	II:4	1974	p.P326L;WT		TPH-1		High
	II:5	1984	WT;WT		GAD, TPH-1		Intermediate
	III:1	1992	p.P326L;WT	V	GPCA		Intermediate
	III:2	2005	p.P326L;WT	V	n.a.	n.a.	Intermediate
G	I:1		n.a	PA	n.a	n.a	n.a
	I:2		n.a	No autoimmunity	n.a	n.a	n.a

	II:1	1934	n.a	No autoimmunity	n.a	n.a	n.a
	II:2		n.a	PA, hypothyroidism, cirrhosis	n.a	n.a	n.a
	II:3		n.a	PA	n.a	n.a	n.a
	III:1	1959	WT;WT	No autoimmunity	n.a	n.a	n.a
	III:2		p.G305S;WT	PA	IF		n.a
	III:3	1972	p.G305S;WT	No autoimmunity	n.a	n.a	n.a
H			p.R316W, p.C322del13;WT	PA			Intermediate
I[g]		1975	p.R328Q;WT	V, low normal B12	GPCA, GAD	n.a.	High

[a]All members of families were analyzed for autoantibodies against 21-OH, 17-OH, GAD, SCC, AADC, TPH-1, TH, NALP-5, IFN-ω, IFN-α2, IL-17F and IL-22, unless otherwise stated.

[b]A, asplenia; AA, alopecia areata; AI, adrenocortical insufficiency; AT, autoimmune thyroid disease; CMC, chronic mucocutaneous candidiasis; EH, enamel hypoplasia; HP, hypoparathyroidism; L, lupus erythematosus disseminates; PA, pernicious anemia; PDI, partial diabetes insipidus; POI, primary ovarian insufficiency; T2D, type 2 diabetes; V, vitiligo. Main components of APS-1 are indicated in **bold**

[c]AADC, aromatic L-amino acid decarboxylase; GAD, glutamic acid decarboxylase; GPCA, gastric parietal cell antibody; ICA, islet cell antibody; IF, intrinsic factor; 17-OH, 17-hydroxylase; 21-OH, 21-hydroxylase; NALP-5, NACHT leucine-rich repeat protein 5; SCC, side-chain cleavage enzyme; TH, tyrosine hydroxylase; TMH, thyroid microsomal hemoagglutinating; TPH-1, tryptophan hydroxylase; n.a., data not available.

[d]IFN-α2, interferon-alpha 2; IFN-ω, interferon-omega; IL-17F; interleukin-17F; IL-22, interleukin-22; n.a., data not available.

[e]Risk assessment for HLA genotypes were defined as in Erichsen et al., JCEM 2009. Full HLA class II haplotypes are given in Supplemental table S5. The genotypes conferring "very high" and "high" risk of developing AI also confer increased risk of developing PA (Lahner et al., Dig Liver Dis 2010).

[f]Initially positive for autoantibodies against AADC, but negative in recent samples.

[g]Immunofluorescence testing for adrenal, ovarian and pituitary autoantibodies was negative, as were anti-mitochondrial, anti-smooth muscle and thyroid peroxidase (TPO) autoantibodies. The patient previously tested positive for autoantibodies against tyrosinase and tyrosinase-related protein 1 and 2.

Table 2. Minor allele frequency (MAF) of missense mutations within AIRE exon 8 (PHD 1 protein domain)

		Norwegian exome data			ExAC Browser			1000 Genomes			Genome Variant Server		
Variant	Protein effect	Allele count	Allele No	MAF	Allele Count	Allele No	MAF	Allele Count	Allele No	MAF	Allele Count	Allele No	MAF
21:45710990 G / A	p.E298K	n.a	n.a	n.a	1	121632	0.000008222			n.a	n.a	n.a	n.a
21:45710995 T / G	p.C299W	n.a	n.a	n.a	1	121584	0.000008225			n.a	n.a	n.a	n.a
21:45710999 G / A rs150634562	p.V301M	3	3340	0.00089	111	121496	0.0009136*	2	5006	0.00039	5	13001	0.00038
21:45711005 C / T	p.R303W	n.a	n.a	n.a	1	121256	0.000008247			n.d	2	13002	0.00015
21:45711006 G / A rs139808903	p.R303Q	n.d	n.d	n.d	22	121228	0.0001815**			n.a	n.a	n.a	n.a
21:45711014 G / A	p.G306R	n.a	n.a	n.a	1	121096	0.000008258			n.a	n.a	n.a	n.a
21:45711025 C / G rs74162062	p.I309M	n.a	n.a	n.a	14	120718	0.0001160^			n.d	n.a	n.a	n.a
21:45711044 C / T	p.R316W	n.a	n.a	n.a	4	119274	0.00003354	2	8596	0.00023	2	13002	0.00015

rs139874934													
21:45711044 C / G rs139874934	p.R316G	n.a	n.a	n.a	1	119274	0.000008384			n.a	n.a	n.a	n.a
21:45711045 G / A	p.R316Q	n.a	n.a	n.a	4	119214	0.00003355	1	760	0.0013	n.a	n.a	n.a
21:45711054 A / C	p.H319P	n.a	n.a	n.a	3	117232	0.00002559			n.a	n.a	n.a	n.a
21:45711075 C/A rs179363885	p.P326Q	n.a	n.a	n.a	n.a	n.a	n.a			n.d	n.a	n.a	n.a
21:45711075 C/T rs179363888	p.P326L	n.a	n.a	n.a	n.a	n.a	n.a			n.d	n.a	n.a	n.a
21:45711080 C / T rs74162063	p.R328W	n.d	n.d	n.d	21	116188	0.0001807^^			n.d	10	12982	0.00077
21:45711081 G / A	p.R328Q	n.a	n.a	n.a	4	116112	0.00003445			n.d	n.a	n.a	n.a
21:45711092 A / C	p.S332R	n.a	n.a	n.a	1	114898	0.000008703			n.a	n.a	n.a	n.a

n.a= not analysed in this dataset

n.d = no frequency determined

*The majority mutations are found in European (minus Finnish), followed by Finnish, South Asian and African populations

**The majority mutations are found in European (minus Finnish), followed by Latino populations

^The majority mutations are found in European (minus Finnish), followed by South Asian population

^^The majority mutations are found in European (minus Finnish), followed by Finnish population